These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 997532)

  • 21. [A field experiment with neuraminidase influenza vaccine (author's transl)].
    Janout V; Uvízl M; Kotíková J; Jukl V
    Cesk Epidemiol Mikrobiol Imunol; 1981 Jul; 30(4):203-12. PubMed ID: 6455206
    [No Abstract]   [Full Text] [Related]  

  • 22. A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.
    Ambrozaitis A; Groth N; Bugarini R; Sparacio V; Podda A; Lattanzi M
    Vaccine; 2009 Oct; 27(43):6022-9. PubMed ID: 19666152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.
    Cox RJ; Madhun AS; Hauge S; Sjursen H; Major D; Kuhne M; Höschler K; Saville M; Vogel FR; Barclay W; Donatelli I; Zambon M; Wood J; Haaheim LR
    Vaccine; 2009 Mar; 27(13):1889-97. PubMed ID: 19368768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
    Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
    J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Safety and immunogenicity of split vaccines of influenza viruses].
    Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Course of antibodies in men after vaccination with the inactivated influenca vaccine Alorbat (author's transl)].
    Pressler K; Schenk KD
    Med Klin; 1978 Sep; 73(38):1321-6. PubMed ID: 703655
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response.
    Oren S; Mandelboim M; Braun-Moscovici Y; Paran D; Ablin J; Litinsky I; Comaneshter D; Levartovsky D; Mendelson E; Azar R; Wigler I; Balbir-Gurman A; Caspi D; Elkayam O
    Ann Rheum Dis; 2008 Jul; 67(7):937-41. PubMed ID: 17981914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines.
    Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R
    Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers.
    de Bruijn IA; Nauta J; Gerez L; Palache AM
    Virus Res; 2004 Jul; 103(1-2):139-45. PubMed ID: 15163502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.
    Holland D; Booy R; De Looze F; Eizenberg P; McDonald J; Karrasch J; McKeirnan M; Salem H; Mills G; Reid J; Weber F; Saville M
    J Infect Dis; 2008 Sep; 198(5):650-8. PubMed ID: 18652550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM; Camilloni B; Basileo M; Neri M; Lepri E; Spighi M
    Gerontology; 2007; 53(6):411-8. PubMed ID: 17975317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
    Ruf BR; Colberg K; Frick M; Preusche A
    Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Complement fixation, hemagglutination inhibition and neuraminidase inhibition reactions in the seroepidemiologic evaluation of an influenza A epidemic].
    Volpi A; Ragona G; Gentile R; Cervelli G; De Felici A; Muzzi A
    Boll Ist Sieroter Milan; 1976 Sep; 55(4):287-91. PubMed ID: 1016581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine.
    Jadhao SJ; Achenbach J; Swayne DE; Donis R; Cox N; Matsuoka Y
    Vaccine; 2008 Mar; 26(14):1742-50. PubMed ID: 18336962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Simultaneous vaccination against influenza and invasive pneumococcal disease in chronic dialysis patients].
    Trmal J; Havlícková M; Bícová R; Bitterová Z; Kelerová J
    Epidemiol Mikrobiol Imunol; 2005 Aug; 54(3):123-8. PubMed ID: 16173523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-neuraminidase antibody response in serum and nasal secretions following intranasal or subcutaneous inactivated A2-Hong Kong-68 influenza virus vaccine.
    Fedson DS; Fulk RV; Huber MA; Reisberg MA; Kasel JA
    J Immunol; 1971 Sep; 107(3):730-7. PubMed ID: 4999093
    [No Abstract]   [Full Text] [Related]  

  • 40. Levels of immunoglobulins and antibodies to haemaglutinin and neuraminidase of influenza virus in nasal secretions after natural infection.
    Hrusková J; Syrůcek L; Tůmová B; Stumpa A; Brůcková M; Losová M; Berkovicová V
    Acta Virol; 1976 Apr; 20(2):126-34. PubMed ID: 5867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.